Innate Pharma S.A.

€1.26As of Sun 8 Nov 2026, 12:00 UTC
EPA:IPHHealthcare
Country France
PE (Fwd) •••
TSR 10Y CAGR (19.25%)
Div yield —
ROE —
Biotechnology
Beta (5Y) 1.22
PE TTM —
TSR TTM (24.88%)
Mkt cap €117.7M
ROIC (2545.08%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
€1.20
(4.60%)
(87.76%)
Hold 7|11|6|12|7
4Q25
1Q26
2Q26
3Q26
Earnings per share€
0.01
0.01
0.01
0.01
15.24%
9.58%
6.34%
9.25%
Revenue€M
5.974
5.807
5.991
6.291
7.26%
2.03%
8.15%
9.76%
Peers (US$132.1M)
Cap (US$)
PE
230.0M
—
102.3M
—
82.04M
—
133.6M
—
Capital
TTM
5Y
10Y
Leveragex
0.095
(0.053)
(0.041)
EBIT/Intx
1.565
0.201
0.173
Own earn%
48.72
(65.43)
(80.42)
Sh yield%
37.10
40.06
37.08
Owners
Insiders/Inst%
7.81
54.45
Short interest%
4.85
SBC / revenue%
3.40
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
12
Op margin range%
2–5
$1 testx
—
Incr. ROIC%
153